<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29898147</article-id><article-id pub-id-type="pmc">5985844</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0157</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Thrombocytopenia After Aortic Valve Replacement: Comparison Between
Sutureless Perceval S Valve and Perimount Magna Ease
Bioprosthesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mujtaba</surname><given-names>Syed Saleem</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Ledingham</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Asif Raza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Schueler</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Pillay</surname><given-names>Thasee</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><aff id="aff1"><label>1</label> Department of Cardiothoracic Surgery, Freeman
Hospital, Freeman Road, United Kingdom of Great Britain and Northern
Ireland.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Syed Saleem Mujtaba, Department of
Cardiothoracic Surgery, Freeman Hospital, Freeman Road Newcastle upon Tyne, NE3
1YS, United Kingdom. E-mail: <email>saleemmujtaba@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2018</year></pub-date><volume>33</volume><issue>2</issue><fpage>169</fpage><lpage>175</lpage><history><date date-type="received"><day>31</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>06</day><month>9</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>The incidence of postoperative thrombocytopenia after aortic valve
replacement (AVR) with the Perceval S Sutureless bioprosthesis remains
unclear. The aim of this study was to report thrombocytopenia associated
with the use of sutureless AVR.</p></sec><sec><title>Methods</title><p>The data was collected retrospectively for patients who had isolated AVR with
sutureless Perceval S valve (Group A: 72 patients) and was compared with
patients who underwent isolated sutured AVR with Perimount Magna Ease
Bioprosthesis (Group B: 101 patients) in our institution between June 2014
and January 2017.</p></sec><sec><title>Results</title><p>Cardiopulmonary bypass and cross-clamp time were significantly shorter in
group A. Maximum drop in platelet count was 58% mean (day 2.3) in group A
<italic>versus</italic> 44% mean (day 1.7) in group B
(<italic>P</italic>=0.0001). Absolute platelet count on postoperative
day 1-6 in group A was significantly less than in group B
(<italic>P</italic>&#x02264;0.05). Platelet count recovered to
preoperative value in 44% patients in group B <italic>versus</italic> only
in 26% patients in group A at discharge (<italic>P</italic>=0.018). Moderate
thrombocytopenia occurs more often in group A (41% <italic>vs.</italic> 26%)
(<italic>P</italic>=0.008) while severe thrombocytopenia (&#x0003c;50 x
10<sup>9</sup>) was observed in 6% in group A but never in group B.
Platelets (<italic>P</italic>=0.007) and packed red blood cells
(<italic>P</italic>=0.009) transfusion was significantly higher in the
group A.</p></sec><sec><title>Conclusion</title><p>The implantation of sutureless Perceval aortic valves was associated with a
significant drop in platelet count postoperatively with slow recovery and
higher platelets and packed red blood cells transfusion requirements. A
prospective randomised trial is needed to confirm our findings.</p></sec></abstract><kwd-group><kwd>Aortic Valve/Surgery</kwd><kwd>Thrombocytopenia</kwd><kwd>Bioprosthesis/ Adverse Effects</kwd><kwd>Heart Valve Prosthesis Implantation/Adverse Effects</kwd></kwd-group></article-meta></front><body><table-wrap id="t10" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Aortic valve
replacement</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ECC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Extracorporeal
circulation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">POD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Postoperative day</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAVI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transcatheter aortic
valve implantation</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Surgical aortic valve replacement (AVR) still represents the gold standard in
patients with severe aortic valve stenosis<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Owing to increasing age of the patient
population in the Western world, there has been an increase in the prevalence of
patients with valvular heart disease eligible for AVR<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Given the increasing
number of co-morbidities and the increasing age of patients, a tendency has emerged
to use biological valve implants thus avoiding the need for long-term
anticoagulation therapy. Although the concept of transcatheter aortic valve
implantation (TAVI) appears attractive, the calcified aortic valve is not removed
during this procedure. Therefore, paravalvular leakage remains an important issue
with this technique<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Other important concerns are access site-related
problems and device malpositioning.</p><p>The recent introduction of sutureless bioprostheses may offer an additional tool in
the therapeutic armamentarium as these valves do not need to be sutured into place
resulting in shorter cross-clamp and cardiopulmonary bypass (CPB) durations which
may be beneficial in older patients with co-morbid conditions. Moreover, due to the
absence of a sewing ring, these valves exhibit favourable hemodynamic properties.
Excellent outcomes have been demonstrated with sutureless AVR in minimally invasive
surgical setting<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>We noticed that sutureless valves are associated with greater drops in postoperative
platelet counts compared to sutured valves. Albacker<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> reported this phenomenon
with sutureless AVR and the aim of this study was to investigate this observation
and try to find an explanation for its occurrence.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Patients</title><p>It is a retrospective, observational study. All the patients who underwent
isolated sutureless Perceval AVR between June 2014 and November 2016 were
compared with patients who had isolated AVR with Carpentier-Edwards Perimount
Magna Ease valve between June 2015 and January 2017. Any non-isolated AVR cases
<italic>i.e</italic>.: coronary artery bypass grafting, mitral and tricuspid
valve surgery, myomectomy, ascending aorta surgery were excluded. Moreover, all
the redo, emergency and infective endocarditis patients were excluded.</p><p>All the sutureless AVRs were performed by the six different surgeons in our
institution during that period. Data was collected on all the patients who
underwent sutured AVR by the same surgeons during the same time period (101
patients) as a control group.</p><p>A total of 72 patients received isolated Perceval bioprosthesis and 101 patients
had Perimount Magna Ease valve. The Percevel S valve sizes were small, medium,
large and extra-large. For statistical purposes they were taken as equivalent to
19-21, 23, 25 and 27 mm Perimount Magna Ease sizes, respectively.</p><p>Severe thrombocytopenia was defined as a platelet count &#x0003c;50x10<sup>9</sup>/Lit
during the postoperative period. The platelet count was determined
preoperatively, day of surgery and every day until day 5 in the postoperative
period. In-hospital mortality was defined as any death occurring within first 30
days after surgery. Aspirin and clopidogrel was discontinued 7 days before
surgery and warfarin was stopped 5 days before operation.</p></sec><sec><title>Surgical Approach</title><p>A complete median sternotomy was performed and extracorporeal circulation (ECC)
with moderate hypothermia (34&#x000ba;C) was employed in every patient. Antegrade cold
blood cardioplegia was administered after application of cross clamp. The choice
of prosthesis implanted was made by the surgeon. Perioperative transesophageal
echocardiogram was performed routinely to confirm correct position of the valve,
exclude any paravalvular leak and evaluate valve hemodynamics.</p><p>The Perimount Magna Ease valve was rinsed with normal saline for 3 minutes before
implantation while Perceval valve does not require any rinsing before
implantation. Perimount Magna Ease valves were intra implanted with interrupted
or semi continuous 2/0 prolene sutures.</p><p>The Perceval valve is a surgical bioprosthetic heart valve consists of
glutaraldehyde-fixed bovine pericardium treated with homocysteic acid in order
to remove the free aldehyde residues and prevent the calcification process. It
is fixed in a metal cage made up of an alloy of nickel and titanium, known as
nitinol.</p><p>Three 4/0 polypropylene guiding sutures were passed at the nadir of the aortic
annulus. An appropriately sized prosthesis was collapsed in a side table and
placed into the manufacturer's holder. The three guiding sutures were passed
through the three green holes arising from the annular ring of the prosthesis,
which was consequently seated on the debrided annulus. Once the delivery system
is in position, the stent is deployed by turning the release screw and leaving
the valve in place. The delivery system and the guiding sutures are removed. The
field was rinsed with warm saline, and the prosthesis was dilated at four
atmospheres for 30 seconds.</p><p>On first postoperative day, patients were started on aspirin 150 mg orally and
low molecular weight heparin subcutaneously for deep vein thrombosis
prophylaxis.</p></sec><sec><title>Statistical Analysis</title><p>All data has been extracted from the Dendrite PATS CS2010F SCTS v4.1.2 database.
Date of data extract was 25.07.17 to cover the period from 01.06.2014 to
31.01.17. Analysis was performed using MS Excel. Numerical values were compared
using an independent t-Test, with a two-tailed distribution assuming unequal
variances. Categorical variables were compared using Chi Square &#x003c7;2
analysis.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The preoperative characteristics of patients are depicted in <xref ref-type="table" rid="t1">Tables 1</xref> and <xref ref-type="table" rid="t2">2</xref>. There was
no difference between Group A and B regarding history of preoperative renal
impairment or pulmonary disease. Group A has more female patients (A=52%
<italic>vs.</italic> B=31%; <italic>P</italic>&#x02264;0.004), patients with
hypertension (79% <italic>vs.</italic> 60%; <italic>P</italic>=0.01), neurological
dysfunction (17% <italic>vs</italic>. 7%; <italic>P</italic>=0.05) and angina (54%
vs. 37%; <italic>P</italic>=0.03). In group A, patients were older (range: 54-84,
mean 74 <italic>vs</italic>. 47-86, mean 70 <italic>vs</italic>. range 34-91, mean
71; <italic>P</italic>=0.001) and with higher logistic EuroSCORE (3.07
<italic>vs</italic>. 1.87; <italic>P</italic>=0.001).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Preoperative summary.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Perceval</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Perimount</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Chi-squared Test</th></tr><tr><th align="left" rowspan="1" colspan="1">Total</th><th align="center" rowspan="1" colspan="1">&#x000a0;n=72</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">&#x000a0;n=101</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender (male/female)</td><td align="center" rowspan="1" colspan="1">34/38</td><td align="center" rowspan="1" colspan="1">47/52%</td><td align="center" rowspan="1" colspan="1">69/31</td><td align="center" rowspan="1" colspan="1">69/31%</td><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Cigarette smoking history</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">4%</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">11%</td><td align="center" rowspan="1" colspan="1">0.106</td></tr><tr><td align="left" rowspan="1" colspan="1">History of hypertension</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">79%</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">60%</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal disease at time of surgery</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1%</td><td align="center" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">History of pulmonary disease (i.e: COPD, asthma)</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">22%</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">19%</td><td align="center" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">History of neurological disease (<italic>i.e</italic>.:
TIA, CVA)</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">17%</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">7%</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Angina Status pre-surgery</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">54%</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">37%</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0. No angina</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">46%</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">88%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. No limitation of physical activity</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">22%</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">25%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Slight limitation of ordinary activity</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">15%</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">15%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Marked limitation of ordinary physical
activity</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">14%</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">8%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;4. Symptoms at rest or minimal activity</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3%</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspnoea status pre-surgery</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">90%</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">82%</td><td align="center" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. No limitation of physical activity</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">10%</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">18%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Slight limitation of ordinary physical
activity</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">32%</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">39%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Marked limitation of ordinary physical
activity</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">57%</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">40%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;4. Symptoms at rest or minimal activity</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1%</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">History of diabetes mellitus</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">18%</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">20%</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative heart rhythm</td><td align="center" colspan="5" rowspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0. Sinus rhythm</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">76%</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">87%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. Atrial fibrillation/flutter</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">22%</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">12%</td><td align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Complete heart block/pacing</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1%</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Other abnormal rhythm</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1.0%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction category</td><td align="center" colspan="5" rowspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. Good (LVEF &#x0003e; 50%)</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">81%</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">84%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Fair (LVEF 30-50%)</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">17%</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">15%</td><td align="center" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Poor (LVEF &#x0003c; 30%)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3%</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1%</td><td align="center" rowspan="1" colspan="1">0.38</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>COPD=chronic obstructive pulmonary disease; CVA=cerebrovascular accident;
LVEF=left ventricular ejection fraction; TIA=transient ischemic attack
</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Preoperative summary (continued).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="30%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="3" rowspan="1">Perceval</th><th align="center" colspan="3" rowspan="1">Perimount</th><th align="center" rowspan="1" colspan="1">t-Test</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">Two-Sample Assuming Unequal Variances</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age of patients at time of procedure</td><td align="center" rowspan="1" colspan="1">54-84</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">47-86</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">70.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistic EuroSCORE comparison</td><td align="center" rowspan="1" colspan="1">0.53-18.89</td><td align="center" rowspan="1" colspan="1">3.07</td><td align="center" rowspan="1" colspan="1">2.41</td><td align="center" rowspan="1" colspan="1">0-7.57</td><td align="center" rowspan="1" colspan="1">1.87</td><td align="center" rowspan="1" colspan="1">1.44</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">140-185</td><td align="center" rowspan="1" colspan="1">164.1</td><td align="center" rowspan="1" colspan="1">163</td><td align="center" rowspan="1" colspan="1">138-185</td><td align="center" rowspan="1" colspan="1">167.3</td><td align="center" rowspan="1" colspan="1">169</td><td align="center" rowspan="1" colspan="1">0.029</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">40.3-158</td><td align="center" rowspan="1" colspan="1">82.2</td><td align="center" rowspan="1" colspan="1">80.1</td><td align="center" rowspan="1" colspan="1">50-181.6</td><td align="center" rowspan="1" colspan="1">84.90</td><td align="center" rowspan="1" colspan="1">81.1</td><td align="center" rowspan="1" colspan="1">0.387</td></tr></tbody></table></table-wrap><p>Greater number of L and XL size valves was implanted in Perceval valve group, and of
23 and 25 mm prosthesis in Perimount Magna Ease group (<xref ref-type="table" rid="t3">Table 3</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Proportion of different valve sizes.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="30%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="30%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Perceval valve sizes</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Perimount Magna valve sizes</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Small</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">Medium</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">42</td></tr><tr><td align="left" rowspan="1" colspan="1">Large</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1">X large&#x000a0;</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">101</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><p>When Perceval valve sizes S, M, L and XL were compared with their counterpart
Perimount Magna Ease valve sizes, there was more significant thrombocytopenia in
Perceval group (<xref ref-type="table" rid="t4">Table 4</xref>). Haematology data is
depicted in <xref ref-type="table" rid="t5">Tables 5</xref>, <xref ref-type="table" rid="t6">6</xref> and <xref ref-type="table" rid="t7">7</xref>. Among the
Perceval valve group, 5 (6%) patients had severe thrombocytopenia. Their peak
reduction was on day 3 with 58% of their preoperative platelet value. While in
Perimount Magna group none of them had severe thrombocytopenia. Their peak reduction
was on day 2 with 44% of preoperative value which is significantly less then
Perceval valve group. Perceval valve group required more blood (1.5
<italic>vs</italic>. 0.7 units) (<italic>P</italic>=0.009) and platelet (0.3
<italic>vs</italic>. 0.1 platelets pools; <italic>P</italic>=0.007) transfusion.
No significant difference in absolute platelet count between two groups on
preoperative and operation days was observed. Platelet count was significantly
reduced in Perceval group from day 1-6 and 20% patients came back to preoperative
level at discharge. Forty-four percent of Perimount patients came back to
preoperative value at the time of discharge. Forty-one percent of Perimount group
had moderate thrombocytopenia while this value was 26% in Perceval valve group.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison of different sizes of valves in respect of drop in platelet count
%.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Perceval valve Size&#x000a0; %</th><th align="center" rowspan="1" colspan="1">Perimount Magna valve Size %</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Small 66.11%</td><td align="center" rowspan="1" colspan="1">19-21 mm 48.36%</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" rowspan="1" colspan="1">Medium 56.28%</td><td align="center" rowspan="1" colspan="1">23 mm 43.25%</td><td align="center" rowspan="1" colspan="1">0.0003</td></tr><tr><td align="center" rowspan="1" colspan="1">Large 59.41%</td><td align="center" rowspan="1" colspan="1">25 mm 44.85%</td><td align="center" rowspan="1" colspan="1">0.0003</td></tr><tr><td align="center" rowspan="1" colspan="1">X large 56.89%</td><td align="center" rowspan="1" colspan="1">27-29 mm 39.3%</td><td align="center" rowspan="1" colspan="1">0.0005</td></tr></tbody></table></table-wrap><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Haematology data.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Perceval valve<break/>N=72</th><th align="center" rowspan="1" colspan="1">Perimount Magna<break/>N=101</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Maximum drop in platelet count: "which day"</td><td align="center" rowspan="1" colspan="1">Mean 2.3<break/>Median 2<break/>Range 0-5</td><td align="center" rowspan="1" colspan="1">Mean 1.7<break/>Median 2<break/>Range 0-6</td><td align="center" rowspan="1" colspan="1">0.0005</td></tr><tr><td align="left" rowspan="1" colspan="1">Maximum drop in platelet count: "what %"</td><td align="center" rowspan="1" colspan="1">Mean 58.0%<break/>Median 58.3%<break/>Range
35-84%</td><td align="center" rowspan="1" colspan="1">Mean 44.3%<break/>Median 45.0%<break/>Range
14-64%</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood transfusion: units</td><td align="center" rowspan="1" colspan="1">Mean 1.5<break/>Median 0.5<break/>Range 0-10</td><td align="center" rowspan="1" colspan="1">Mean 0.7<break/>Median 0<break/>Range 0-8</td><td align="center" rowspan="1" colspan="1">0.0091</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet transfusion: pool of platelets</td><td align="center" rowspan="1" colspan="1">Mean 0.3<break/>Median 0<break/>Range 0-4</td><td align="center" rowspan="1" colspan="1">Mean 0.1<break/>Median 0<break/>Range 0-2</td><td align="center" rowspan="1" colspan="1">0.0075</td></tr><tr><td align="left" rowspan="1" colspan="1">FFP Transfusion: units</td><td align="center" rowspan="1" colspan="1">Mean 0.2<break/>Median 0<break/>Range 0-4</td><td align="center" rowspan="1" colspan="1">Mean 0.1<break/>Median 0<break/>Range 0-3</td><td align="center" rowspan="1" colspan="1">0.21</td></tr></tbody></table></table-wrap><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Haematology data (continued).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Patients having postoperative thrombocytopenia</th><th align="center" rowspan="1" colspan="1">Perimount Magna valve</th><th align="center" rowspan="1" colspan="1">Perceval valve</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Moderate thrombocytopenia: &#x0003c;100 x 109</td><td align="center" rowspan="1" colspan="1">N=26 (26%)</td><td align="center" rowspan="1" colspan="1">N=34 (41%)</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe thrombocytopenia: &#x0003c;50 x 109</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">N=5 (6%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients whose platelet level returned to preoperative
level following surgery/did not return to preoperative</td><td align="center" rowspan="1" colspan="1">Perimount Magna valve<break/>N=44/57 (44/56%)</td><td align="center" rowspan="1" colspan="1">Perceval valve<break/>N=20/56 (26/74%)</td><td align="center" rowspan="1" colspan="1">0.018</td></tr></tbody></table></table-wrap><table-wrap id="t7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Absolute platelet count on preoperative, operative and postoperative
days.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Platelet count on days</th><th align="center" rowspan="1" colspan="1">Perimount Magna valve</th><th align="center" rowspan="1" colspan="1">Perceval valve</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Preoperative platelet count</td><td align="center" rowspan="1" colspan="1">244</td><td align="center" rowspan="1" colspan="1">239.8</td><td align="center" rowspan="1" colspan="1">=0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Operation day platelet count</td><td align="center" rowspan="1" colspan="1">158.6</td><td align="center" rowspan="1" colspan="1">144.6</td><td align="center" rowspan="1" colspan="1">=0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 1 platelet count</td><td align="center" rowspan="1" colspan="1">158.7</td><td align="center" rowspan="1" colspan="1">132.8</td><td align="center" rowspan="1" colspan="1">=0.0007</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 2 platelet count</td><td align="center" rowspan="1" colspan="1">145.9</td><td align="center" rowspan="1" colspan="1">112.8</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 3 platelet count</td><td align="center" rowspan="1" colspan="1">158.4</td><td align="center" rowspan="1" colspan="1">111.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 4 platelet count</td><td align="center" rowspan="1" colspan="1">183.5</td><td align="center" rowspan="1" colspan="1">130.0</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 5 platelet count</td><td align="center" rowspan="1" colspan="1">216.4</td><td align="center" rowspan="1" colspan="1">157.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 6 platelet count</td><td align="center" rowspan="1" colspan="1">260.3</td><td align="center" rowspan="1" colspan="1">174.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative day 7 platelet count</td><td align="center" rowspan="1" colspan="1">254.6</td><td align="center" rowspan="1" colspan="1">205.7</td><td align="center" rowspan="1" colspan="1">=0.23</td></tr></tbody></table></table-wrap><p>Intraoperative and early postoperative variables are summarized in <xref ref-type="table" rid="t8">Tables 8</xref> and <xref ref-type="table" rid="t9">9</xref>. Cross clamp (range 23-76 min, mean 39 min <italic>vs</italic>. 24-133
min, mean 54 min; <italic>P</italic>=0.001)) and bypass time (range 25-119 min, mean
59 min <italic>vs</italic>. range 19-175 min, mean 71 min; <italic>P</italic>=0.001)
were shorter in isolated Perceval valve group (Group A1) compared to isolated
conventional valve group (Group B1).</p><table-wrap id="t8" orientation="portrait" position="float"><label>Table 8</label><caption><p>Intraoperative and early postoperative data.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="30%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="3" rowspan="1">Perceval</th><th align="center" colspan="3" rowspan="1">Perimount</th><th align="center" rowspan="1" colspan="1">t-Test: Two-Sample Assuming Unequal Variances</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cumulative cross-clamp time (min)</td><td align="center" rowspan="1" colspan="1">23-76</td><td align="center" rowspan="1" colspan="1">39.2</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">24-133</td><td align="center" rowspan="1" colspan="1">54.1</td><td align="center" rowspan="1" colspan="1">48.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Cumulative bypass time</td><td align="center" rowspan="1" colspan="1">25-119</td><td align="center" rowspan="1" colspan="1">59.3</td><td align="center" rowspan="1" colspan="1">56.5</td><td align="center" rowspan="1" colspan="1">19-175</td><td align="center" rowspan="1" colspan="1">71.6</td><td align="center" rowspan="1" colspan="1">63.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Post operative blood loss @ 12 hours</td><td align="center" rowspan="1" colspan="1">15-2000</td><td align="center" rowspan="1" colspan="1">304</td><td align="center" rowspan="1" colspan="1">212.5</td><td align="center" rowspan="1" colspan="1">100-2000</td><td align="center" rowspan="1" colspan="1">359.7</td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">0.197</td></tr><tr><td align="left" rowspan="1" colspan="1">ITU stay in days</td><td align="center" rowspan="1" colspan="1">1-13</td><td align="center" rowspan="1" colspan="1">3.2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1-17</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.005</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>ITU=intensive care unit</p></fn></table-wrap-foot></table-wrap><table-wrap id="t9" orientation="portrait" position="float"><label>Table 9</label><caption><p>Intraoperative and early postoperative data (continued).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Perceval</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Perimount</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Chi-squared Test</th></tr><tr><th align="left" rowspan="1" colspan="1">Total</th><th align="center" rowspan="1" colspan="1">n=72</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n=100</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Reoperation for bleeding, tamponade</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2.78%</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2.00%</td><td align="center" rowspan="1" colspan="1">0.738</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient status at discharge (mortality)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1.39%</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">0.00%</td><td align="center" rowspan="1" colspan="1">0.237</td></tr></tbody></table></table-wrap><p>Perceval valve patients spent more time in ICU compared to Perimount Magna patients
(3.2 days <italic>vs</italic>. 1.9 days; <italic>P</italic>=0.005). No significant
difference in postoperative neurological dysfunction, renal impairment, atrial
fibrillation, permanent pacemaker requirement or mortality could be observed.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our retrospective study showed that there is a relationship between Perceval S valve
implantation and severe thrombocytopenia. Severe thrombocytopenia in our study was
not associated with higher mortality and morbidity, and none of these deaths was
related to severe thrombocytopenia.</p><p>S&#x000e1;nchez et al.<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> compared the incidence of thrombocytopenia after AVR
with Perceval S Sutureless Bioprosthesis (n=27) and Mitroflow prostheses (n=50). The
incidence of severe thrombocytopenia was significantly higher
(<italic>P</italic>=0.046) in Perceval S patients than in Mitroflow patients. The
platelet count recovered in all patients with severe thrombocytopenia.</p><p>The biological structure of the Perceval S valve and Freedom Solo stentless
bioprosthesis are very similar<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>Hilker et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> compared the postoperative courses of platelet
counts in patients having had AVR with stentless prostheses (Sorin Biomedica Freedom
Solo [SOLO]) or stented prostheses (Carpentier Edwards Perimount [PM]). A higher
occurrence of platelet levels below 100 Gpt/l between the second and the fifth
postoperative day (POD) was found in the SOLO-group (71.9%) compared with the other
biological substitute PM (36.6%).</p><p>Miceli et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> evaluated the postoperative evolution of platelet
count and function after AVR in 116 patients undergoing isolated stentless
biological AVR with Freedom Solo and compared with 206 patients who received stented
biological valves. Freedom Solo implantation was associated with a higher incidence
of thrombocytopenia compared with the control group (24.1% <italic>vs</italic>.
4.4%, <italic>P</italic>&#x0003c;0.0001).</p><p>Piccardo et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> also studied the incidence and clinical impact of
thrombocytopenia in patients receiving AVR with Freedom Solo bioprosthesis and
Carpentier-Edwards Perimount pericardial prosthesis. They reported that severe
thrombocytopenia occurred in 25% and 3% of patients with Freedom Solo and Perimount
bioprostheses, respectively (<italic>P</italic>&#x0003c;0.0001).</p><p>Yerebakan et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> compared platelet counts within 2 weeks after
implantation of either a stentless (Sorin Freedom Solo) or a stented (Sorin
Mitroflow) bovine pericardial bioprosthesis. In the Mitroflow group, the mean
platelet count moderately dropped to a minimum of 60% of the initial value on
3<sup>rd</sup> POD and fully recovered on 8<sup>th</sup> POD. In the Freedom
Solo group, platelet loss was significantly more severe (minimum relative value 25%
on 4<sup>th</sup> POD) with no recovery during follow-up. However, there were no
other complications reported in association with thrombocytopenia related to the use
of these Freedom Solo valves and the phenomenon was transient and resolved without
clinical consequences or hemodynamic dysfunction<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>Platelet count decrease has also been reported after percutaneous coronary
intervention<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Gallet et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> studied the effect of
transcatheter (via femoral artery) aortic valve implantation (TAVI) on platelet
count. They observed that platelet count systematically decreased after TAVI, with
an average decrease of 34&#x000b1;15%, and a decrease in platelet count reported to
be associated with in-hospital major adverse cardiovascular events and strongly
influenced patient outcome. In the setting of TAVI procedures platelet activation
can be caused by endothelial damage caused by prosthesis implantation, fibrinogen
binding on metallic armatures, and shear stress modifications due to prosthesis
implantation<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p><p>Van Straten et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup> compared thrombocytopenia after AVR with mechanical
and biological valves. They concluded that patients undergoing AVR with the
Carpentier-Edwards Perimount bioprosthesis or a Medtronic Freestyle stentless
bioprosthesis had a lower minimum platelet count within the first five POD, compared
to patients receiving ATS and St. Jude Medical mechanical prostheses.</p><p>In our study, the drop-in platelet count started to occur during the 3<sup>rd</sup>
POD with very slow recovery toward the 7<sup>th</sup> to 10<sup>th</sup> POD. The
lowest drop in platelet count was down to 22% of the preoperative baseline level and
occurred in patients implanted with the Perceval valve. As shown in other studies,
there were no other clinical consequences associated with thrombocytopenia that was
transient but resulted in more transfusion requirements.</p><p>The bovine pericardium leaflets of both Perceval S valve and Mitroflow bioprosthesis
are fixed in a process using gluteraldehyde. The Mitroflow prosthesis is stored in a
solution of gluteraldehyde and needs rinsing before it is used. On the other side,
the Perceval S prosthesis and Freedom Solo prosthesis are detoxified with
homocysteic acid to eliminate any residual aldehyde and then stored in an aldehyde
free solution; so, it does not require rinsing prior to use. Homocysteic acid can
have a damaging effect on vessel endothelial cells and can precipitate platelet
aggregation resulting in both thrombocytopenia and thrombotic
complications<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. These valves are carefully washed after
detoxification with a homocysteic acid-free solution and then stored in jars filled
with a homocysteic acid-free storage solution. Consequently, the residual amount of
homocysteic acid, which could be transferred to the patient during the valve
implantation, is negligible and the resulting concentration in blood is extremely
low, so cannot be blamed for the postoperative thrombocytopenia. Moreover, the same
solution is used for other bioprosthesis<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>, without causing higher incidence of
thrombocytopenia.</p><p>Mechanical stress and hemodynamic turbulence have also been proposed as a cause of
thrombocytopenia after Freedom Solo prosthesis<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>Small valve sizes have been described as causing some turbulence across the valve
resulting in platelet activation or destruction, and consequently postoperative
thrombocytopenia<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>. However, sutureless valves are well known for
their superior hemodynamic performance and this hypothesis is quite unlikely.</p><p>Non-specific activation of platelets leading to diffuse consumption and
thrombocytopenia after AVR with both mechanical and bioprosthetic aortic valves was
suggested by Leguyader et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Platelet activation could also result from
valve manipulation or the presence of the metal stent.</p><p>The Perceval S valve has metal structure that serves as an anchoring system to the
aortic valve, which could be the cause of turbulent flow, platelet rupture and
mechanical structure. The metal stent may play a role in platelet activation and the
possibility of paravalvular leaks may also trigger platelet activation and
consumption. Moreover, the metal stents of these valves could interfere with the
quality of images and could conceal or underestimate the degree of some paravalvular
leaks<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>Long CPB duration has been suggested by other studies to be associated with
postoperative thrombocytopenia<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. In our study the CPB durations were shorter in
the sutureless group than the sutured one so it cannot be responsible for
post-operative thrombocytopenia.</p><p>Severe thrombocytopenia is a common complication in patients who undergo cardiac
surgery with ECC. It occurs as result of structural changes and activation of
platelets, hemodilution, platelet aggregation and bleeding<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>.</p><sec><title>Limitations</title><p>The main limitation of our study is due to its observational, non-randomized and
retrospective characteristics. Heparin induced thrombocytopenia was not
investigated as a possible cause of thrombocytopenia, as it appears after the
5<sup>th</sup> postoperative day<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>It seems to be an association between sutureless Perceval valve and severe
thrombocytopenia, although it does not affect patient's mortality and morbidity.
These patients had also higher rate of blood and platelets transfusion. A
prospective randomised trial is needed to confirm our findings.</p><table-wrap id="t11" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">SSM</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SL</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ARS</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SS</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SC</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TP</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Department of Cardiothoracic Surgery, Freeman
Hospital, Freeman Road, United Kingdom of Great Britain and Northern
Ireland.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahanian</surname><given-names>A</given-names></name><name><surname>Alfieri</surname><given-names>O</given-names></name><name><surname>Andreotti</surname><given-names>F</given-names></name><name><surname>Antunes</surname><given-names>MJ</given-names></name><name><surname>Bar&#x000f3;n-Esquivias</surname><given-names>G</given-names></name><name><surname>Baumgartner</surname><given-names>H</given-names></name><etal/></person-group><article-title>Guidelines on the management of valvular heart disease (version
2012): the Joint Task Force on the Management of Valvular Heart Disease of
the European Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS)</article-title><source>Eur J Cardiothorac Surg</source><year>2012</year><volume>42</volume><issue>4</issue><fpage>S1</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22922698</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bridgewater</surname><given-names>B</given-names></name><name><surname>Gummert</surname><given-names>J</given-names></name><name><surname>Kinsman</surname><given-names>R</given-names></name><name><surname>Walton</surname><given-names>P</given-names></name></person-group><source>Towards global benchmarking: the Fourth EACTS Adult Cardiac Surgical
Database Report</source><publisher-loc>Oxfordshire</publisher-loc><publisher-name>Dendrite Clinical Systems, Henley-on-Thames</publisher-name><year>2010</year></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martens</surname><given-names>S</given-names></name><name><surname>Sadowski</surname><given-names>J</given-names></name><name><surname>Eckstein</surname><given-names>FS</given-names></name><name><surname>Bartus</surname><given-names>K</given-names></name><name><surname>Kapelak</surname><given-names>B</given-names></name><name><surname>Sievers</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Clinical experience with the ATS 3f Enable&#x000ae; sutureless
bioprosthesis</article-title><source>Eur J Cardiothorac Surg</source><year>2011</year><volume>40</volume><issue>3</issue><fpage>749</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">21342776</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santarpino</surname><given-names>G</given-names></name><name><surname>Pfeiffer</surname><given-names>S</given-names></name><name><surname>Concistr&#x000e8;</surname><given-names>G</given-names></name><name><surname>Fischlein</surname><given-names>T</given-names></name></person-group><article-title>Perceval S aortic valve implantation in mini-invasive surgery:
the simple sutureless solution</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2012</year><volume>15</volume><issue>3</issue><fpage>357</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">22617506</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albacker</surname><given-names>TB</given-names></name></person-group><article-title>Thrombocytopenia associated with Perceval sutureless aortic valve
replacement in elderly patients: a word of caution</article-title><source>Heart Surg Forum</source><year>2015</year><volume>18</volume><issue>3</issue><fpage>E093</fpage><lpage>E097</lpage><pub-id pub-id-type="pmid">26115151</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>E</given-names></name><name><surname>Corrales</surname><given-names>JA</given-names></name><name><surname>Fantidis</surname><given-names>P</given-names></name><name><surname>Tarhini</surname><given-names>IS</given-names></name><name><surname>Khan</surname><given-names>I</given-names></name><name><surname>Pineda</surname><given-names>T</given-names></name><etal/></person-group><article-title>Thrombocytopenia after aortic valve replacement with Perceval S
sutureless bioprosthesis</article-title><source>J Heart Valve Dis</source><year>2016</year><volume>25</volume><issue>1</issue><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">27989089</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilker</surname><given-names>L</given-names></name><name><surname>Wodny</surname><given-names>M</given-names></name><name><surname>Ginesta</surname><given-names>M</given-names></name><name><surname>Wollert</surname><given-names>HG</given-names></name><name><surname>Eckel</surname><given-names>L</given-names></name></person-group><article-title>Differences in the recovery of platelet counts after biological
aortic valve replacement</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2009</year><volume>8</volume><issue>1</issue><fpage>70</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">18842699</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miceli</surname><given-names>A</given-names></name><name><surname>Gilmanov</surname><given-names>D</given-names></name><name><surname>Murzi</surname><given-names>M</given-names></name><name><surname>Parri</surname><given-names>MS</given-names></name><name><surname>Cerillo</surname><given-names>AG</given-names></name><name><surname>Bevilacqua</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evaluation of platelet count after isolated biological aortic
valve replacement with Freedom Solo bioprosthesis</article-title><source>Eur J Cardiothorac Surg</source><year>2012</year><volume>41</volume><issue>1</issue><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">21664141</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccardo</surname><given-names>A</given-names></name><name><surname>Rusinaru</surname><given-names>D</given-names></name><name><surname>Petitprez</surname><given-names>B</given-names></name><name><surname>Marticho</surname><given-names>P</given-names></name><name><surname>Vaida</surname><given-names>I</given-names></name><name><surname>Tribouilloy</surname><given-names>C</given-names></name><etal/></person-group><article-title>Thrombocytopenia after aortic valve replacement with freedom solo
bioprosthesis: a propensity study</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>89</volume><issue>5</issue><fpage>1425</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">20417755</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yerebakan</surname><given-names>C</given-names></name><name><surname>Kaminski</surname><given-names>A</given-names></name><name><surname>Westphal</surname><given-names>B</given-names></name><name><surname>Kundt</surname><given-names>G</given-names></name><name><surname>Ugurlucan</surname><given-names>M</given-names></name><name><surname>Steinhoff</surname><given-names>G</given-names></name><etal/></person-group><article-title>Thrombocytopenia after aortic valve replacement with Freedom Solo
stentless bioprosthesis</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2008</year><volume>7</volume><issue>4</issue><fpage>616</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">18505752</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Labriolle</surname><given-names>A</given-names></name><name><surname>Bonello</surname><given-names>L</given-names></name><name><surname>Lemesle</surname><given-names>G</given-names></name><name><surname>Roy</surname><given-names>P</given-names></name><name><surname>Steinberg</surname><given-names>DH</given-names></name><name><surname>Xue</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Decline in platelet count in patients treated by percutaneous
coronary intervention: definition, incidence, prognostic importance, and
predictive factors</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>9</issue><fpage>1079</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">20089516</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallet</surname><given-names>R</given-names></name><name><surname>Seemann</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Hayat</surname><given-names>D</given-names></name><name><surname>Mouillet</surname><given-names>G</given-names></name><name><surname>Monin</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Effect of transcatheter (via femoral artery) aortic valve
implantation on the platelet count and its consequences</article-title><source>Am J Cardiol</source><year>2013</year><volume>111</volume><issue>11</issue><fpage>1619</fpage><lpage>1624</lpage><pub-id pub-id-type="pmid">23523059</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobili</surname><given-names>M</given-names></name><name><surname>Sheriff</surname><given-names>J</given-names></name><name><surname>Morbiducci</surname><given-names>U</given-names></name><name><surname>Redaelli</surname><given-names>A</given-names></name><name><surname>Bluestein</surname><given-names>D</given-names></name></person-group><article-title>Platelet activation due to hemodynamic shear stresses: damage
accumulation model and comparison to in vitro measurements</article-title><source>ASAIO J</source><year>2008</year><volume>54</volume><issue>1</issue><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">18204318</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Straten</surname><given-names>AH</given-names></name><name><surname>Hamad</surname><given-names>MA</given-names></name><name><surname>Berreklouw</surname><given-names>E</given-names></name><name><surname>ter Woorst</surname><given-names>JF</given-names></name><name><surname>Martens</surname><given-names>EJ</given-names></name><name><surname>Tan</surname><given-names>ME</given-names></name></person-group><article-title>Thrombocytopenia after aortic valve replacement: comparison
between mechanical and biological valves</article-title><source>J Heart Valve Dis</source><year>2010</year><volume>19</volume><issue>3</issue><fpage>394</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">20583405</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccardo</surname><given-names>A</given-names></name><name><surname>Rusinaru</surname><given-names>D</given-names></name><name><surname>Petitprez</surname><given-names>B</given-names></name><name><surname>Marticho</surname><given-names>P</given-names></name><name><surname>Vaida</surname><given-names>I</given-names></name><name><surname>Tribouilloy</surname><given-names>C</given-names></name><etal/></person-group><article-title>Thrombocytopenia after aortic valve replacement with freedom solo
bioprosthesis: a propensity study</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>89</volume><issue>5</issue><fpage>1425</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">20417755</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santarpino</surname><given-names>G</given-names></name><name><surname>Pfeiffer</surname><given-names>S</given-names></name><name><surname>Fischlein</surname><given-names>T</given-names></name></person-group><article-title>Thrombocytopenia after freedom solo: the mystery goes
on</article-title><source>Ann Thorac Surg</source><year>2011</year><volume>91</volume><issue>1</issue><fpage>330</fpage><lpage>330</lpage></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leguyader</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>R</given-names></name><name><surname>Berb&#x000e9;</surname><given-names>J</given-names></name><name><surname>Boumediene</surname><given-names>A</given-names></name><name><surname>Cogn&#x000e9;</surname><given-names>M</given-names></name><name><surname>Laskar</surname><given-names>M</given-names></name></person-group><article-title>Platelet activation after aortic prosthetic valve
surgery</article-title><source>Interact Cardiovasc Surg</source><year>2006</year><volume>5</volume><issue>1</issue><fpage>60</fpage><lpage>64</lpage></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weerasinghe</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>KM</given-names></name></person-group><article-title>The platelet in cardiopulmonary bypass</article-title><source>Ann Thorac Surg</source><year>1998</year><volume>66</volume><issue>6</issue><fpage>2145</fpage><lpage>2152</lpage><pub-id pub-id-type="pmid">9930521</pub-id></element-citation></ref></ref-list></back></article>